Securities Star data Center News, Kailiying rose the limit to close, closing price 357.39 yuan. The stock rose by the limit at 11:26, opened the limit four times, and closed with a capital of 45.4275 million yuan, accounting for 0.05 per cent of its current market value.
In terms of capital flow data, the net inflow of main funds on the same day was 48.8033 million yuan, the net inflow of hot capital was 57.5657 million yuan, and the net outflow of retail funds was 22.453 million yuan. The flow of funds in the past five days is shown in the following table:
The stock is a hot stock of innovative drugs, pharmaceuticals and chemical API concepts. On the same day, innovative drug concepts rose 3.23%, pharmaceutical concepts rose 2.4%, and chemical API concepts rose 2.39%.
The investment logic of the stock is as follows:
1. One of the leaders in the domestic CMO industry, engaged in customized R & D and customized production of one-stop CDMO services for a number of domestic pharmaceutical companies to provide 1.1 new drug R & D services; representative new drug projects include: treatment of hepatitis C, cardiovascular disease, cystic fibrosis and other projects Signing a strategic cooperation framework agreement with Covance, an American drug research and development company, will provide customers with one-stop service for new drug research and development, and carry out long-term and in-depth cooperation in drug discovery, preclinical trials, clinical trials, drug registration and large-scale production. In May 20, it is proposed to introduce Hillhouse Capital Management Co., Ltd. as a strategic investor and sign a conditional effective strategic cooperation agreement with Hillhouse Capital Management Co., Ltd., to carry out in-depth strategic cooperation in the business areas of small molecules, nucleic acids, biopharmaceutical CDMO and innovative drug clinical research services.
2. One of the leaders in the domestic CMO industry, engaged in customized R & D and customized production of one-stop CDMO services for a number of domestic pharmaceutical companies to provide 1.1 new drug R & D services; representative new drug projects include the treatment of hepatitis C, cardiovascular disease, cystic fibrosis and other projects
3. The world's leading provider of CDMO solutions, mainly committed to technological innovation and commercial application of global pharmaceutical processes, providing one-stop CMC services for drug research and development and production for large and medium-sized pharmaceutical and biotechnology enterprises at home and abroad. In 19 years, CDMO business revenue was 2.224 billion yuan, accounting for 90.42%.
From the perspective of financial situation, Kelleying 2021 China report showed that the company's main income was 1.76 billion yuan, up 39.04% from the same period last year; net profit from its mother was 429 million yuan, up 36.03% from the same period last year; deducting 353 million yuan from non-net profit, up 27.29% from the same period last year; debt ratio 16.42%, investment income 15.4517 million yuan, financial expenses 194500 yuan, gross profit margin 44.88%.
The Securities Star valuation analysis tool shows that the stock has a good company rating of 4 stars, a good price rating of 1.5 stars and a comprehensive valuation rating of 3 stars.
Disclaimer: the relevant content according to the public big data analysis, does not constitute investment advice, the stock market is risky, investment should be cautious.